ApoB
ApoB (apolipoprotein B, also written ApoB-100) is the main structural apolipoprotein of chylomicrons, LDL and VLDL. It acts as the ligand through which LDL particles are recognised by the LDL receptor, and it is encoded by the APOB gene. Browse Assay Genie's current range of ApoB research reagents below, or read on for the biology behind the target.
ApoB is a major protein constituent of chylomicrons, low density lipoprotein (LDL) and very low density lipoprotein (VLDL). In LDL and VLDL the protein is present as apoB-100, which serves as a recognition signal for the cellular binding and internalisation of LDL particles by the apoB/E receptor. In chylomicrons the protein is present as the shorter apoB-48. The ApoB protein is annotated in UniProt as occurring in the cytoplasm, in secreted form and at lipid droplets.
The APOB gene produces two main plasma isoforms, apoB-48 and apoB-100, from a single, very long mRNA. ApoB-48 is synthesised exclusively in the gut, whereas apoB-100 is synthesised in the liver. The two isoforms share a common N-terminal sequence. The shorter apoB-48 arises after RNA editing of the apoB-100 transcript at residue 2180 (CAA to UAA), which creates a stop codon and causes early translation termination. This makes ApoB a classic example of tissue-specific RNA editing determining protein form.
Mutations in the APOB gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, all of which affect plasma cholesterol and apoB levels. HGNC places the gene in the apolipoproteins group and records a previous name, apolipoprotein B (including Ag(x) antigen). Mouse and rat both carry an orthologous Apob gene, so the protein is also studied in rodent models.
ApoB is the main apolipoprotein of chylomicrons, LDL and VLDL, making it central to studies of how lipoprotein particles are assembled and handled.
ApoB-100 is the ligand recognised by the apoB/E receptor, so it is used to study LDL binding and cellular internalisation.
APOB mutations cause hypobetalipoproteinemia and hypercholesterolemia due to ligand-defective apoB, linking the protein to plasma cholesterol disorders.
Editing of the APOB transcript at residue 2180 yields gut-specific apoB-48 alongside hepatic apoB-100, a well-defined model of tissue-specific isoform control.
ApoB is a major structural protein of chylomicrons, LDL and VLDL. The apoB-100 form acts as a recognition signal for the binding and internalisation of LDL particles by the apoB/E receptor, also called the LDL receptor, which is how cells take up LDL.
Both come from one APOB gene and one long mRNA and share an N-terminal sequence. ApoB-100 is made in the liver. ApoB-48 is made only in the gut after RNA editing at residue 2180 (CAA to UAA) creates a stop codon and ends translation early.
Mutations in APOB or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia and hypercholesterolemia due to ligand-defective apoB. Mouse and rat both have an Apob ortholog; check the datasheet of any product for its validated reactivity.
Other apolipoprotein-related and APOBEC-family targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P04114; product specifications from Assay Genie datasheets.